Cryosite (ASX:CTE) Total Equity: A$3.61 Mil (As of Dec. 2025)


ASX:CTE Cryosite Ltd ASX:CTE
51 GF Score
Price A$1.15
GF Value A$0.94
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cryosite Total Equity?

Cryosite ASX:CTE 51 Total Equity is A$3.61 Mil as of Dec. 2025. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Cryosite's total equity for the quarter that ended in Dec. 2025 was A$3.61 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Cryosite Total Equity Historical Data

* Premium members only.

The historical data trend for Cryosite's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryosite Total Equity Chart

Cryosite Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 1.86 2.78 1.45 2.39

Cryosite Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.90 1.45 1.31 2.39 3.61
ASX:CTE
51GF Score
Cryosite Ltd ASX:CTE
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryosite Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Cryosite's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=19.464-17.075
=2.39

Cryosite's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=26.545-22.936
=3.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of A$3.61 Mil mean?
Cryosite (ASX:CTE) has a Total Equity of A$3.61 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Cryosite and its competitors.
Is Cryosite's Total Equity too high?
Cryosite's current Total Equity is A$3.61 Mil. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Total Equity compare to TMO and DHR?
Cryosite's Total Equity of A$3.61 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Cryosite and its competitors. Cryosite's current Total Equity is A$3.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current Total Equity is A$3.61 Mil. Cryosite's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Total Equity is A$3.61 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryosite (ASX:CTE) Overvalued in 2026?

Based on GuruFocus' analysis, Cryosite stock appears to be overvalued. The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94. GuruFocus considers Cryosite to be Modestly Overvalued.

Key valuation signals for ASX:CTE:

  • Total Equity: A$3.61 Mil
  • GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryosite Business Description

Address 13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score

Get the complete analysis for ASX:CTE

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.15
Price
A$0.94
GF Value